The regulatory loopholes governing alternative medicine products in Canada represent a public safety issue. In 2017 and 2018, the Liver Transplant Program of the University of British Columbia assessed three patients with acute liver failure secondary to alternative medicines. As health care professionals, we have a duty to both recognize the magnitude of the problem and advocate for reform of the current regulatory process for alternative medicine products.